Works by Laubach, Jacob P.

Results: 37
    1

    Selinexor: Targeting a novel pathway in multiple myeloma.

    Published in:
    EJHaem, 2023, v. 4, n. 3, p. 792, doi. 10.1002/jha2.709
    By:
    • Mo, Clifton C.;
    • Yee, Andrew J.;
    • Midha, Shonali;
    • Hartley‐Brown, Monique A.;
    • Nadeem, Omar;
    • O'Donnell, Elizabeth K.;
    • Bianchi, Giada;
    • Sperling, Adam S.;
    • Laubach, Jacob P.;
    • Richardson, Paul G.
    Publication type:
    Article
    2

    Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib.

    Published in:
    EJHaem, 2020, v. 1, n. 1, p. 1, doi. 10.1002/jha2.4
    By:
    • Richardson, Paul G.;
    • Nagler, Arnon;
    • Ben-Yehuda, Dina;
    • Badros, Ashraf;
    • Hari, Parameswaran N.;
    • Hajek, Roman;
    • Spicka, Ivan;
    • Kaya, Hakan;
    • LeBlanc, Richard;
    • Sung-Soo Yoon;
    • Kihyun Kim;
    • Martinez-Lopez, Joaquin;
    • Moshe Mittelman;
    • Shpilberg, Ofer;
    • Blake, Paul;
    • Teru Hideshima;
    • Colson, Kathleen;
    • Laubach, Jacob P.;
    • Ghobrial, Irene M.;
    • Leiba, Merav
    Publication type:
    Article
    3
    4

    Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-024-55308-5
    By:
    • Nadeem, Omar;
    • Aranha, Michelle P.;
    • Redd, Robert;
    • Timonian, Michael;
    • Magidson, Sophie;
    • Lightbody, Elizabeth D.;
    • Alberge, Jean-Baptiste;
    • Bertamini, Luca;
    • Dutta, Ankit K.;
    • El-Khoury, Habib;
    • Bustoros, Mark;
    • Laubach, Jacob P.;
    • Bianchi, Giada;
    • O'Donnell, Elizabeth;
    • Wu, Ting;
    • Tsuji, Junko;
    • Anderson, Kenneth C.;
    • Getz, Gad;
    • Trippa, Lorenzo;
    • Richardson, Paul G.
    Publication type:
    Article
    5

    The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.

    Published in:
    European Journal of Haematology, 2012, v. 88, n. 5, p. 446, doi. 10.1111/j.1600-0609.2012.01765.x
    By:
    • Richardson, Paul G.;
    • Laubach, Jacob P.;
    • Schlossman, Robert L.;
    • Ghobrial, Irene M.;
    • Redman, Katherine C.;
    • Mckenney, Mary;
    • Warren, Diane;
    • Noonan, Kimberly;
    • Lunde, Laura;
    • Doss, Deborah;
    • Colson, Kathleen;
    • Hideshima, Teru;
    • Mitsiades, Constantine;
    • Munshi, Nikhil C.;
    • Anderson, Kenneth C.
    Publication type:
    Article
    6
    7

    Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma.

    Published in:
    American Journal of Hematology, 2022, v. 97, n. 5, p. 562, doi. 10.1002/ajh.26491
    By:
    • O'Gorman, Peter;
    • Laubach, Jacob P.;
    • O'Dwyer, Michael E.;
    • Krawczyk, Janusz;
    • Yee, Andrew J.;
    • Gilligan, Oonagh;
    • Cahill, Mary R.;
    • Rosenblatt, Jacalyn;
    • Quinn, John;
    • Murphy, Philip T.;
    • DiPietro, Heidi;
    • Perera, Meegahage Ratnakanthi;
    • Crotty, Gerard M.;
    • Cummings, Kristen;
    • Hayden, Patrick J.;
    • Browne, Paul;
    • Savell, Alexandra;
    • O'Leary, Hilary M.;
    • O'Keeffe, Denis;
    • Masone, Kelly
    Publication type:
    Article
    8
    9

    Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.

    Published in:
    American Journal of Hematology, 2019, v. 94, n. 11, p. 1244, doi. 10.1002/ajh.25627
    By:
    • Ghobrial, Irene M.;
    • Liu, Chia‐Jen;
    • Zavidij, Oksana;
    • Azab, Abdel K.;
    • Baz, Rachid;
    • Laubach, Jacob P.;
    • Mishima, Yuji;
    • Armand, Philippe;
    • Munshi, Nikhil C.;
    • Basile, Frank;
    • Constantine, Michael;
    • Vredenburgh, James;
    • Boruchov, Adam;
    • Crilley, Pamela;
    • Henrick, Patrick M.;
    • Hornburg, Kalvis T. V.;
    • Leblebjian, Houry;
    • Chuma, Stacey;
    • Reyes, Kaitlen;
    • Noonan, Kimberly
    Publication type:
    Article
    10

    IgM myeloma: A multicenter retrospective study of 134 patients.

    Published in:
    American Journal of Hematology, 2017, v. 92, n. 8, p. 746, doi. 10.1002/ajh.24753
    By:
    • Castillo, Jorge J.;
    • Jurczyszyn, Artur;
    • Brozova, Lucie;
    • Crusoe, Edvan;
    • Czepiel, Jacek;
    • Davila, Julio;
    • Dispenzieri, Angela;
    • Eveillard, Marion;
    • Fiala, Mark A.;
    • Ghobrial, Irene M.;
    • Gozzetti, Alessandro;
    • Gustine, Joshua N.;
    • Hajek, Roman;
    • Hungria, Vania;
    • Jarkovsky, Jiri;
    • Jayabalan, David;
    • Laubach, Jacob P.;
    • Lewicka, Barbara;
    • Maisnar, Vladimir;
    • Manasanch, Elisabet E.
    Publication type:
    Article
    11
    12
    13
    14

    Ixazomib for the treatment of multiple myeloma.

    Published in:
    Expert Opinion on Pharmacotherapy, 2018, v. 19, n. 17, p. 1949, doi. 10.1080/14656566.2018.1528229
    By:
    • Richardson, Paul G.;
    • Zweegman, Sonja;
    • O'Donnell, Elizabeth K.;
    • Laubach, Jacob P.;
    • Raje, Noopur;
    • Voorhees, Peter;
    • Ferrari, Renda H.;
    • Skacel, Tomas;
    • Kumar, Shaji K.;
    • Lonial, Sagar
    Publication type:
    Article
    15
    16

    Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.

    Published in:
    British Journal of Haematology, 2014, v. 166, n. 3, p. 401, doi. 10.1111/bjh.12909
    By:
    • Yee, Andrew J.;
    • Hari, Parameswaran;
    • Marcheselli, Raffaella;
    • Mahindra, Anuj K.;
    • Cirstea, Diana D.;
    • Scullen, Tyler A.;
    • Burke, Jill N.;
    • Rodig, Scott J.;
    • Hideshima, Teru;
    • Laubach, Jacob P.;
    • Ghobrial, Irene M.;
    • Schlossman, Robert L.;
    • Munshi, Nikhil C.;
    • Anderson, Kenneth C.;
    • Weller, Edie A.;
    • Richardson, Paul G.;
    • Raje, Noopur S.
    Publication type:
    Article
    17
    18

    The power of proteasome inhibition in multiple myeloma.

    Published in:
    Expert Review of Proteomics, 2018, v. 15, n. 12, p. 1033, doi. 10.1080/14789450.2018.1543595
    By:
    • Guerrero-Garcia, Thomas A.;
    • Gandolfi, Sara;
    • Laubach, Jacob P.;
    • Hideshima, Teru;
    • Chauhan, Dharminder;
    • Mitsiades, Constantine;
    • Anderson, Kenneth C.;
    • Richardson, Paul G.
    Publication type:
    Article
    19

    Bortezomib in the management of multiple myeloma.

    Published in:
    Cancer Management & Research, 2009, v. 1, p. 107
    By:
    • Laubach, Jacob P.;
    • Mitsiades, Constantine S.;
    • Hideshima, Teru;
    • Schlossman, Robert;
    • Chauhan, Dharminder;
    • Munshi, Nikhil;
    • Ghobrial, Irene;
    • Carreau, Nicole;
    • Anderson, Kenneth C.;
    • Richardson, Paul G.
    Publication type:
    Article
    20
    21

    Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma.

    Published in:
    Cancer (0008543X), 2022, v. 128, n. 10, p. 1996, doi. 10.1002/cncr.34134
    By:
    • O'Donnell, Elizabeth K.;
    • Shapiro, Yael N.;
    • Yee, Andrew J.;
    • Nadeem, Omar;
    • Hu, Bonnie Y.;
    • Laubach, Jacob P.;
    • Branagan, Andrew R.;
    • Anderson, Kenneth C.;
    • Mo, Clifton C.;
    • Munshi, Nikhil C.;
    • Ghobrial, Irene M.;
    • Sperling, Adam S.;
    • Agyemang, Emerentia A.;
    • Burke, Jill N.;
    • Harrington, Cynthia C.;
    • Richardson, Paul G.;
    • Raje, Noopur S.;
    • El‐Jawahri, Areej
    Publication type:
    Article
    22
    23
    24

    Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study.

    Published in:
    British Journal of Haematology, 2019, v. 186, n. 3, p. e35, doi. 10.1111/bjh.15879
    By:
    • Plesner, Torben;
    • Arkenau, Hendrik‐Tobias;
    • Gay, Francesca;
    • Minnema, Monique C.;
    • Boccadoro, Mario;
    • Moreau, Philippe;
    • Cavenagh, Jamie;
    • Perrot, Aurore;
    • Laubach, Jacob P.;
    • Krejcik, Jakub;
    • Ahmadi, Tahamtan;
    • Boer, Carla;
    • Chen, Diana;
    • Chiu, Christopher;
    • Schecter, Jordan M.;
    • Richardson, Paul G.
    Publication type:
    Article
    25

    A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma.

    Published in:
    British Journal of Haematology, 2018, v. 182, n. 2, p. 222, doi. 10.1111/bjh.15261
    By:
    • O'Donnell, Elizabeth K.;
    • Laubach, Jacob P.;
    • Yee, Andrew J.;
    • Chen, Tianqi;
    • Huff, Carol Ann;
    • Basile, Frank G.;
    • Wade, Philip M.;
    • Paba‐Prada, Claudia E.;
    • Ghobrial, Irene M.;
    • Schlossman, Robert L.;
    • Burke, Jill N.;
    • Harrington, Cynthia C.;
    • Lively, Kathleen J.;
    • Lyons, Hannah F.;
    • Munshi, Nikhil C.;
    • Anderson, Kenneth C.;
    • Trippa, Lorenzo;
    • Richardson, Paul G.;
    • Raje, Noopur S.
    Publication type:
    Article
    26
    27

    Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.

    Published in:
    British Journal of Haematology, 2018, v. 180, n. 6, p. 821, doi. 10.1111/bjh.15058
    By:
    • Richardson, Paul G.;
    • Bensinger, William I.;
    • Huff, Carol Ann;
    • Costello, Caitlin L.;
    • Lendvai, Nikoletta;
    • Berdeja, Jesus G.;
    • Anderson Jr., Larry D.;
    • Siegel, David S.;
    • Lebovic, Daniel;
    • Jagannath, Sundar;
    • Laubach, Jacob P.;
    • Stockerl-Goldstein, Keith E.;
    • Long Kwei;
    • Fong Clow;
    • Elias, Laurence;
    • Zeena, Zeena;
    • Graef, Thorsten;
    • Bilotti, Elizabeth;
    • Vij, Ravi
    Publication type:
    Article
    28
    29

    A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

    Published in:
    British Journal of Haematology, 2017, v. 178, n. 4, p. 547, doi. 10.1111/bjh.14708
    By:
    • Laubach, Jacob P.;
    • Moslehi, Javid J.;
    • Francis, Sanjeev A.;
    • San Miguel, Jesús F.;
    • Sonneveld, Pieter;
    • Orlowski, Robert Z.;
    • Moreau, Philippe;
    • Rosiñol, Laura;
    • Faber, Edward A.;
    • Voorhees, Peter;
    • Mateos, Maria ‐ Victoria;
    • Marquez, Loreta;
    • Feng, Huaibao;
    • Desai, Avinash;
    • Velde, Helgi;
    • Elliott, Jennifer;
    • Shi, Hongliang;
    • Dow, Edward;
    • Jobanputra, Nishith;
    • Esseltine, Dixie ‐ Lee
    Publication type:
    Article
    30
    31
    32

    Deacetylase inhibitors: an advance in myeloma therapy?

    Published in:
    Expert Review of Hematology, 2017, v. 10, n. 3, p. 229, doi. 10.1080/17474086.2017.1280388
    By:
    • Laubach, Jacob P.;
    • San-Miguel, Jesus F.;
    • Hungria, Vania;
    • Hou, Jian;
    • Moreau, Philippe;
    • Lonial, Sagar;
    • Lee, Jae Hoon;
    • Einsele, Hermann;
    • Alsina, Melissa;
    • Richardson, Paul G.
    Publication type:
    Article
    33
    34
    35
    36
    37

    Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.

    Published in:
    European Journal of Haematology, 2019, v. 102, n. 6, p. 494, doi. 10.1111/ejh.13231
    By:
    • Dimopoulos, Meletios A.;
    • Laubach, Jacob P.;
    • Richardson, Paul G.;
    • Echeveste Gutierrez, Maria Asunción;
    • Grzasko, Norbert;
    • Hofmeister, Craig C.;
    • San‐Miguel, Jesus F.;
    • Kumar, Shaji;
    • Labotka, Richard;
    • Lu, Vickie;
    • Berg, Deborah;
    • Byrne, Catriona;
    • Teng, Zhaoyang;
    • Liu, Guohui;
    • Velde, Helgi
    Publication type:
    Article